Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ACE | P12821 | 3/20 | 0.42 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20583297 | 1.00 | ALDH1A1 (0.47) | ALDH1A1MAPTHPGDLMNAABCC4 | |
| SCHEMBL20583508 | 0.85 | ALDH1A1 (0.50) | ALDH1A1MAPTHPGDLMNAABCC4 | |
| SCHEMBL20583510 | 0.85 | ALDH1A1 (0.50) | ALDH1A1MAPTHPGDLMNAABCC4 | |
| SCHEMBL21572798 | 0.83 | ALDH1A1 (0.52) | ALDH1A1MAPTHPGDLMNAABCC4 | |
| SCHEMBL21572805 | 0.82 | ALDH1A1 (0.48) | ALDH1A1MAPTHPGDLMNAABCC4 | |
| SCHEMBL21572811 | 0.81 | ALDH1A1 (0.58) | ALDH1A1MAPTHPGDLMNACYP1A2 | |
| SCHEMBL18970304 | 0.81 | ABCC4 (0.55) | ALDH1A1MAPTHPGDLMNAABCC4 | |
| SCHEMBL18970284 | 0.81 | ABCC4 (0.55) | ALDH1A1MAPTHPGDLMNAABCC4 | |
| SCHEMBL22295411 | 0.80 | LMNA (0.53) | ALDH1A1MAPTHPGDLMNAABCC4 | |
| SCHEMBL20583484 | 0.79 | ALDH1A1 (0.50) | ALDH1A1MAPTHPGDLMNAABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-06-28 | — | — | US | disclosed |
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-06-28 | — | — | US | disclosed |
| EP-3424899-B1 | SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-05-11 | — | — | EP | disclosed |
| EP-3424899-B1 | SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-05-11 | — | — | EP | disclosed |
| CN-106977415-B | Intermediate of shakubiqu and preparation method thereof | 广东东阳光药业有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20200079721-A1 | SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF | NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED (HK) | 2020-03-12 | — | — | US | disclosed |
| US-10479753-B2 | Sacubitril intermediate and preparation method thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2019-11-19 | — | — | US | disclosed |
| US-10479753-B2 | Sacubitril intermediate and preparation method thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2019-11-19 | — | — | US | disclosed |
| EP-3424899-A1 | SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2019-01-09 | — | — | EP | disclosed |
| US-20180362439-A1 | SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079721-A1 | SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF | DPP4, ACE, DPP8 | ALDH1A1 308/4885MAPT 1710/4885HPGD 1169/4885 |
| US-20180362439-A1 | SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF | ACE, DPP4, SI | ALDH1A1 339/4885MAPT 1322/4885HPGD 1551/4885 |
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | DPP4, ACE, DPP8 | ALDH1A1 308/4885MAPT 1710/4885HPGD 1169/4885 |
| US-10479753-B2 | Sacubitril intermediate and preparation method thereof | ACE, DPP4, SI | ALDH1A1 339/4885MAPT 1322/4885HPGD 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.